On July 27, 2022 Cortexyme, Inc. (Nasdaq: CRTX) reported that the company’s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022 (Press release, Quince Therapeutics, JUL 27, 2022, View Source [SID1234619482]). In conjunction with the corporate name change, the company plans to issue a news release that will provide a business update detailing Quince Therapeutics’ go-forward growth strategy and development pipeline plans.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Additionally, the company’s ticker symbol on the Nasdaq Global Select Market is expected change to "QNCX" effective at the open of market trading on Monday, August 1, 2022. The company’s common stock will continue to trade under the ticker symbol "CRTX" until market close on Friday, July 29, 2022. The corporate name change to Quince Therapeutics does not affect the rights of the company’s stockholders. Outstanding stock certificates are not affected by the name change and will not need to be exchanged.

Quince Therapeutics also plans to launch its new corporate website and social media presence on Twitter and LinkedIn on Monday, August 1, 2022.